Literature DB >> 9461038

Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors.

S M Hellwig1, C A Damen, N P van Adrichem, G H Blijham, G Groenewegen, A W Griffioen.   

Abstract

We report the suppressed vascular CD34 expression in renal cell carcinoma. This was found by quantitatively analyzing CD34 expression on normal and tumor derived EC by flow cytometry. In vitro studies revealed that culture of umbilical cord or dermis derived microvascular EC with angiogenic factors such as basic fibroblast growth factor (bFGF) and vascular endothelial cell growth factor induced downregulation of CD34. This angiogenesis-induced downregulated expression of CD34 adhesion molecule may contribute to the tumor mediated escape mechanism from immune surveillance. It is concluded that there are quantitative differences in expression of endothelial CD34 in different compartments of the vasculature, that angiogenic factors affect this expression and that subpopulations of EC exist with differences in EAM expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9461038     DOI: 10.1016/s0304-3835(97)00310-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

Review 2.  Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Authors:  Rakesh R Ramjiawan; Arjan W Griffioen; Dan G Duda
Journal:  Angiogenesis       Date:  2017-03-30       Impact factor: 9.596

3.  Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression.

Authors:  Sandra I Zittermann; Andrew C Issekutz
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

4.  Oral metronomic cyclophosphamide in elderly with metastatic melanoma.

Authors:  Estelle Borne; Eve Desmedt; Alain Duhamel; Xavier Mirabel; Véronique Dziwniel; Cyril Maire; Valérie Florin; Véronique Martinot; Nicolas Penel; Sophie Vercambre-Darras; Laurent Mortier
Journal:  Invest New Drugs       Date:  2009-08-12       Impact factor: 3.850

5.  PADI4 and tumourigenesis.

Authors:  Xiaotian Chang; Kehua Fang
Journal:  Cancer Cell Int       Date:  2010-03-12       Impact factor: 5.722

6.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.

Authors:  H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

7.  Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines.

Authors:  Pei-Suen Tsou; Bradley J Rabquer; Ray A Ohara; William A Stinson; Phillip L Campbell; M Asif Amin; Beatrix Balogh; George Zakhem; Paul A Renauer; Ann Lozier; Eshwar Arasu; G Kenneth Haines; Bashar Kahaleh; Elena Schiopu; Dinesh Khanna; Alisa E Koch
Journal:  Rheumatology (Oxford)       Date:  2015-12-24       Impact factor: 7.580

8.  Hepatocellular carcinoma, novel therapies on the horizon.

Authors:  Imane El Dika; Iman Makki; Ghassan K Abou-Alfa
Journal:  Chin Clin Oncol       Date:  2020-06-09

9.  CD34 marks angiogenic tip cells in human vascular endothelial cell cultures.

Authors:  Martin J Siemerink; Ingeborg Klaassen; Ilse M C Vogels; Arjan W Griffioen; Cornelis J F Van Noorden; Reinier O Schlingemann
Journal:  Angiogenesis       Date:  2012-01-17       Impact factor: 9.596

Review 10.  Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.

Authors:  Mannon Geindreau; François Ghiringhelli; Mélanie Bruchard
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.